GLP-1RAs not associated with increased risk for suicidal thoughts or behaviors

A target trial emulation study found no increased risk for suicidal thoughts or behaviors associated with the use of GLP-1RAs (glucagon-like peptide-1 receptor agonists) to treat type 2 diabetes (T2D). 

Read More